Cellular Therapy and Induced Neuronal Replacement for Huntington's Disease

Neurotherapeutics

Volumn 8, Issue 4, 2011, Pages 577-590

  Benraiss, Abdellatif ^a   Goldman, Steven A ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Cell therapy; Medium spiny neuron; Neural transplants; Neurogenesis; Stem cells

Indexed keywords

BONE MORPHOGENETIC PROTEIN; HUNTINGTIN; POLYGLUTAMINE;

ALLOGRAFT; CELL DEATH; CELL THERAPY; CELL TRANSPLANTATION; CYTOTOXICITY; EMBRYONIC STEM CELL; FETUS CELL; HUNTINGTON CHOREA; NERVE CELL DEGENERATION; PRIORITY JOURNAL; REVIEW; STEM CELL MOBILIZATION;

ANIMALS; BONE MORPHOGENETIC PROTEINS; BRAIN; CELL TRANSPLANTATION; EMBRYONIC STEM CELLS; HUMANS; HUNTINGTON DISEASE; NEURONS; PLURIPOTENT STEM CELLS;

EID: 80955131284     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-011-0075-8     Document Type: Review

References (149)

1. Peschanski M, Cesaro P, Hantraye P. Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease. Neuroscience 1995; 68: 273-285.
2. Traficante A, Riozzi B, Cannella M, Rampello L, Squitieri F, Battaglia G. Reduced activity of cortico-striatal fibres in the R6/2 mouse model of Huntington's disease. Neuroreport 2007; 18: 1997-2000.
3. Gauthier LR, Charrin BC, Borrell-Pages M, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004; 118: 127-138.
4. Kopyov OV, Jacques S, Lieberman A, Duma CM, Eagle KS. Safety of intrastriatal neurotransplantation for Huntington's disease patients. Exp Neurol 1998; 149: 97-108.
5. Pundt LL, Kondoh T, Conrad JA, Low WC. Transplantation of human striatal tissue into a rodent model of Huntington's disease: phenotypic expression of transplanted neurons and host-to-graft innervation. Brain Res Bull 1996; 39: 23-32.
6. Borlongan CV, Koutouzis TK, Poulos SG, Saporta S, Sanberg PR. Bilateral fetal striatal grafts in the 3-nitropropionic acid-induced hypoactive model of Huntington's disease. Cell Transplant 1998; 7: 131-135.
7. Hurelbrink CB, Armstrong RJ, Dunnett SB, Rosser AE, Barker RA. Neural cells from primary human striatal xenografts migrate extensively in the adult rat CNS. Eur J Neurosci 2002; 15: 1255-1266.
8. Wictorin K, Ouimet CC, Bjorklund A. Intrinsic Organization and connectivity of intrastriatal striatal transplants in rats as revealed by DARPP-32 immunohistochemistry: specificity of connections with the lesioned host brain. Eur J Neurosci 1989; 1: 690-701.
9. Palfi S, Conde F, Riche D, et al. Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease. Nat Med 1998; 4: 963-966.
10. Bachoud-Levi AC, Remy P, Nguyen JP, et al. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 2000; 356: 1975-1979.
11. Gaura V, Bachoud-Levi AC, Ribeiro MJ, et al. Striatal neural grafting improves cortical metabolism in Huntington's disease patients. Brain 2004; 127(part 1): 65-72.
12. Bachoud-Levi AC, Gaura V, Brugieres P, et al. Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. Lancet Neurol 2006; 5: 303-309.
13. Hauser RA, Furtado S, Cimino CR, et al. Bilateral human fetal striatal transplantation in Huntington's disease. Neurology 2002; 58: 687-695.
14. Furtado S, Sossi V, Hauser RA, et al. Positron emission tomography after fetal transplantation in Huntington's disease. Ann Neurol 2005; 58: 331-337.
15. Cicchetti F, Soulet D, Freeman TB. Neuronal degeneration in striatal transplants and Huntington's disease: potential mechanisms and clinical implications. Brain 2011; 134(part 3): 641-652.
16. Rosser AE, Barker RA, Harrower T, et al. Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475. J Neurol Neurosurg Psychiatry 2002; 73: 678-685.
17. Dunnett SB, Rosser AE. Cell transplantation for Huntington's disease Should we continue? Brain Res Bull 2007; 72: 132-147.
18. Reuter I, Tai YF, Pavese N, et al. Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease. J Neurol Neurosurg Psychiatry 2008; 79: 948-951.
19. Capetian P, Knoth R, Maciaczyk J, et al. Histological findings on fetal striatal grafts in a Huntington's disease patient early after transplantation. Neuroscience 2009; 160: 661-675.
20. Gallina P, Paganini M, Lombardini L, et al. Human striatal neuroblasts develop and build a striatal-like structure into the brain of Huntington's disease patients after transplantation. Exp Neurol 2010; 222: 30-41.
21. Kawaguchi Y. Neostriatal cell subtypes and their functional roles. Neurosci Res 1997; 27: 1-8.
22. Kubota Y, Hattori R, Yui Y. Three distinct subpopulations of GABAergic neurons in rat frontal agranular cortex. Brain Res 1994; 649: 159-173.
23. Krystkowiak P, Gaura V, Labalette M, et al. Alloimmunisation to donor antigens and immune rejection following foetal neural grafts to the brain in patients with Huntington's disease. PLoS One 2007; 2: e166.
24. Pakzaban P, Deacon TW, Burns LH, Isacson O. Increased proportion of acetylcholinesterase-rich zones and improved morphological integration in host striatum of fetal grafts derived from the lateral but not the medial ganglionic eminence. Exp Brain Res 1993; 97: 13-22.
25. Watts C, Brasted PJ, Dunnett SB. Embryonic donor age and dissection influences striatal graft development and functional integration in a rodent model of Huntington's disease. Exp Neurol 2000; 163: 85-97.
26. Cicchetti F, Saporta S, Hauser RA, et al. Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proc Natl Acad Sci U S A 2009; 106: 12483-12488.
27. Broadwell RD, Charlton HM, Ebert P, Hickey WF, Villegas JC, Wolf AL. Angiogenesis and the blood-brain barrier in solid and dissociated cell grafts within the CNS. Prog Brain Res 1990; 82: 95-101.
28. Kirik D, Bjorklund A. Histological analysis of fetal dopamine cell suspension grafts in two patients with Parkinson's disease gives promising results. Brain 2005; 128(part 7): 1478-1479.
29. Watts C, Brasted PJ, Dunnett SB. The morphology, integration, and functional efficacy of striatal grafts differ between cell suspensions and tissue pieces. Cell Transplant 2000; 9: 395-407.
30. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008; 14: 504-506.
31. Isacson O, Deacon TW, Pakzaban P, Galpern WR, Dinsmore J, Burns LH. Transplanted xenogeneic neural cells in neurodegenerative disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres. Nat Med 1995; 1: 1189-1194.
32. Mendez I, Sanchez-Pernaute R, Cooper O, et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 2005; 128(part 7): 1498-1510.
33. Baker-Cairns BJ, Sloan DJ, Broadwell RD, Puklavec M, Charlton HM. Contributions of donor and host blood vessels in CNS allografts. Exp Neurol 1996; 142: 36-46.
34. Nakao N, Grasbon-Frodl EM, Widner H, Brundin P. DARPP-32-rich zones in grafts of lateral ganglionic eminence govern the extent of functional recovery in skilled paw reaching in an animal model of Huntington's disease. Neuroscience 1996; 74: 959-970.
35. Wang S, Roy NS, Benraiss A, Goldman SA. Promoter-based isolation and fluorescence-activated sorting of mitotic neuronal progenitor cells from the adult mammalian ependymal/subependymal zone. Dev Neurosci 2000; 22: 167-176.
36. Keyoung HM, Roy NS, Benraiss A, et al. High-yield selection and extraction of two promoter-defined phenotypes of neural stem cells from the fetal human brain. Nat Biotechnol 2001; 19: 843-850.
37. Wang S, Chandler-Militello D, Lu G, et al. Prospective identification, isolation, and profiling of a telomerase-expressing subpopulation of human neural stem cells, using sox2 enhancer-directed fluorescence-activated cell sorting. J Neurosci 2010; 30: 14635-14648.
38. Windrem MS, Nunes MC, Rashbaum WK, et al. Fetal and adult human oligodendrocyte progenitor cell isolates myelinate the congenitally dysmyelinated brain. Nat Med 2004; 10: 93-97.
39. Windrem MS, Roy NS, Wang J, et al. Progenitor cells derived from the adult human subcortical white matter disperse and differentiate as oligodendrocytes within demyelinated lesions of the rat brain. J Neurosci Res 2002; 69: 966-975.
40. Aubry L, Bugi A, Lefort N, Rousseau F, Peschanski M, Perrier AL. Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats. Proc Natl Acad Sci USA 2008; 105: 16707-16712.
41. Roy NS, Cleren C, Singh SK, Yang L, Beal MF, Goldman SA. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med 2006; 12: 1259-1268.
42. Bjorklund LM, Sanchez-Pernaute R, Chung S, et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci U S A 2002; 99: 2344-2349.
43. Barberi T, Klivenyi P, Calingasan NY, et al. Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nat Biotechnol 2003; 21: 1200-1207.
44. Erdo F, Buhrle C, Blunk J, et al Host-dependent tumorigenesis of embryonic stem cell transplantation in experimental stroke. J Cereb Blood Flow Metab 2003; 23: 780-785.
45. Brederlau A, Correia AS, Anisimov SV, et al. Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: effect of in vitro differentiation on graft survival and teratoma formation. Stem Cells 2006; 24: 1433-1440.
46. Ko JY, Lee HS, Park CH, Koh HC, Lee YS, Lee SH. Conditions for tumor-free and dopamine neuron-enriched grafts after transplanting human ES cell-derived neural precursor cells. Mol Ther 2009; 17: 1761-1770.
47. Ben-Hur T, Idelson M, Khaner H, et al. Transplantation of human embryonic stem cell-derived neural progenitors improves behavioral deficit in Parkinsonian rats. Stem Cells 2004; 22: 1246-1255.
48. Sanchez-Pernaute R, Studer L, Ferrari D, et al. Long-term survival of dopamine neurons derived from parthenogenetic primate embryonic stem cells (cyno-1) after transplantation. Stem Cells 2005; 23: 914-922.
49. Draper JS, Pigott C, Thomson JA, Andrews PW. Surface antigens of human embryonic stem cells: changes upon differentiation in culture. J Anat 2002; 200(part 3): 249-258.
50. Drukker M, Katz G, Urbach A, et al. Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci U S A 2002; 99: 9864-9869.
51. Drukker M, Benvenisty N. The immunogenicity of human embryonic stem-derived cells. Trends Biotechnol 2004; 22: 136-141.
52. Ideguchi M, Shinoyama M, Gomi M, Hayashi H, Hashimoto N, Takahashi J. Immune or inflammatory response by the host brain suppresses neuronal differentiation of transplanted ES cell-derived neural precursor cells. J Neurosci Res 2008; 86: 1936-1943.
53. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-1920.
54. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
55. Kim D, Kim CH, Moon JI, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009; 4: 472-476.
56. Germain N, Banda E, Grabel L. Embryonic stem cell neurogenesis and neural specification. J Cell Biochem 2010; 111: 535-542.
57. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011; 474: 212-215.
58. Beyene R, Boockvar JA. Disease-specific induced pluripotent stem cells. Neurosurgery 2008; 63: 12.
59. Park IH, Arora N, Huo H, et al. Disease-specific induced pluripotent stem cells. Cell 2008; 134: 877-886.
60. Zhang N, An MC, Montoro D, Ellerby LM. Characterization of Human huntington's disease cell model from induced pluripotent stem cells. PLoS Curr 2010; 2: RRN1193.
61. Ebert AD, Svendsen CN. Stem cell model of spinal muscular atrophy. Arch Neurol 2010; 67: 665-669.
62. Wernig M, Zhao JP, Pruszak J, et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci U S A 2008; 105: 5856-5861.
63. Hargus G, Cooper O, Deleidi M, et al. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci U S A 2010; 107: 15921-15926.
64. Hussein SM, Batada NN, Vuoristo S, et al. Copy number variation and selection during reprogramming to pluripotency. Nature 2011; 471: 58-62.
65. Gore A, Li Z, Fung HL, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011; 471: 63-67.
66. Lister R, Pelizzola M, Kida YS, et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011; 471: 68-73.
67. Luskin MB. Restricted proliferation and migration of postnatally generated neurons derived from the forebrain subventricular zone. Neuron 1993; 11: 173-189.
68. Lois C, Alvarez-Buylla A. Long-distance neuronal migration in the adult mammalian brain. Science 1994; 264: 1145-1148.
69. Lois C, Garcia-Verdugo JM, Alvarez-Buylla A. Chain migration of neuronal precursors. Science 1996; 271: 978-981.
70. Doetsch F, Alvarez-Buylla A. Network of tangential pathways for neuronal migration in adult mammalian brain. Proc Natl Acad Sci U S A 1996; 93: 14895-14900.
71. Doetsch F, Garcia Verdugo JM, Alvarez Buylla A. Cellular composition and three-dimensional organization of the subventricular germinal zone in the adult mammalian brain 1. J Neurosci 1997; 17: 5046.
72. Garcia-Verdugo JM, Doetsch F, Wichterle H, Lim DA, Alvarez-Buylla A. Architecture and cell types of the adult subventricular zone: in search of the stem cells. J Neurobiol 1998; 36: 234-248.
73. Doetsch F, Caille I, Lim DA, Garcia-Verdugo JM, Alvarez-Buylla A. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 1999; 97: 703-716.
74. Doetsch F. The glial identity of neural stem cells. 2003; 6: 1127-1134.
75. Goldman S. Glia as neural progenitor cells. Trends in Neurosci 2003; 26: 590-596.
76. Alvarez-Buylla A, Garcia-Verdugo JM. Neurogenesis in adult subventricular zone. J Neurosci 2002; 22: 629-634.
77. Cameron HA, Woolley CS, McEwen BS, Gould E. Differentiation of newly born neurons and glia in the dentate gyrus of the adult rat. Neuroscience 1993; 56: 337-344.
78. Whitman MC, Greer CA. Adult neurogenesis and the olfactory system. Prog Neurobiol 2009; 89: 162-175.
79. Abrous DN, Koehl M, Le Moal M. Adult neurogenesis: from precursors to network and physiology. Physiol Rev 2005; 85: 523-569.
80. Cameron HA, McKay RD. Adult neurogenesis produces a large pool of new granule cells in the dentate gyrus. J Comp Neurol 2001; 435: 406-417.
81. Kato T, Yokouchi K, Fukushima N, Kawagishi K, Li Z, Moriizumi T. Continual replacement of newly-generated olfactory neurons in adult rats. Neurdosci Lett 2001; 307: 17-20.
82. Kempermann G, Kuhn HG, Gage FH. More hippocampal neurons in adult mice living in an enriched environment. Nature 1997; 386: 493-495.
83. Seri B, Garcia-Verdugo JM, Collado-Morente L, McEwen BS, Alvarez-Buylla A. Cell types, lineage, and architecture of the germinal zone in the adult dentate gyrus. J Comp Neurol 2004; 478: 359-378.
84. Kuhn HG, Winkler J, Kempermann G, Thal LJ, Gage FH. Epidermal growth factor and fibroblast growth factor-2 have different effects on neural progenitors in the adult rat brain. J Neurosci 1997; 17: 5820-5829.
85. Reynolds BA, Tetzlaff W, Weiss S. A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes. J Neurosci 1992; 12: 4565-4574.
86. Seroogy KB, Gall CM, Lee DC, Kornblum HI. Proliferative zones of postnatal rat brain express epidermal growth factor receptor mRNA. Brain Res 1995; 670: 157-164.
87. Gritti A, Frolichsthal-Schoeller P, Galli R, et al. Epidermal and fibroblast growth factors behave as mitogenic regulators for a single multipotent stem cell-like population from the subventricular region of the adult mouse forebrain. J Neurosci 1999; 19: 3287-3297.
88. Kornblum HI, Hussain RJ, Bronstein JM, Gall CM, Lee DC, Seroogy KB. Prenatal ontogeny of the epidermal growth factor receptor and its ligand, transforming growth factor alpha, in the rat brain. J Comp Neurol 1997; 380: 243-261.
89. Tropepe V, Craig CG, Morshead CM, van der Kooy D. Transforming growth factor-alpha null and senescent mice show decreased neural progenitor cell proliferation in the forebrain subependyma. J Neurosci 1997; 17: 7850-7859.
90. Zheng W, Nowakowski RS, Vaccarino FM. Fibroblast growth factor 2 is required for maintaining the neural stem cell pool in the mouse brain subventricular zone. Dev Neurosci 2004; 26: 181-196.
91. Jin K, Sun Y, Xie L, et al. Neurogenesis and aging: FGF-2 and HB-EGF restore neurogenesis in hippocampus and subventricular zone of aged mice. Aging Cell 2003; 2: 175-183.
92. Doetsch F, Petreanu L, Caille I, Garcia-Verdugo JM, Alvarez-Buylla A. EGF converts transit-amplifying neurogenic precursors in the adult brain into multipotent stem cells. Neuron 2002; 36: 1021-1034.
93. Craig CG, Tropepe V, Morshead CM, Reynolds BA, Weiss S, van der Kooy D. In vivo growth factor expansion of endogenous subependymal neural precursor cell populations in the adult mouse brain. J Neurosci 1996; 16: 2649-2658.
94. Tao Y, Black IB, DiCicco-Bloom E. In vivo neurogenesis is inhibited by neutralizing antibodies to basic fibroblast growth factor. J Neurobiol 1997; 33: 289-296.
95. Tao Y, Black IB, DiCicco-Bloom E. Neurogenesis in neonatal rat brain is regulated by peripheral injection of basic fibroblast growth factor (bFGF). J Comp Neurol 1996; 376: 653-663.
96. Jin K, LaFevre-Bernt M, Sun Y, et al. FGF2 promotes neurogenesis and neuroprotection in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci U S A 2005; 102: 18189-18194.
97. Batista CM, Kippin TE, Willaime-Morawek S, Shimabukuro MK, Akamatsu W, van der Kooy D. A progressive and cell non-autonomous increase in striatal neural stem cells in the Huntington's disease R6/2 mouse. J Neurosci 2006; 26: 10452-10460.
98. Cho SR, Benraiss A, Chmielnicki E, Samdani A, Economides A, Goldman SA. Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease. J Clin Invest 2007; 117: 2889-2902.
99. Glass M, Dragunow M, Faull RL. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000; 97: 505-519.
100. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000; 101: 57-66.
101. Pastrana E, Moreno-Flores MT, Avila J, Wandosell F, Minichiello L, Diaz-Nido J. BDNF production by olfactory ensheathing cells contributes to axonal regeneration of cultured adult CNS neurons. Neurochem Int 2007; 50: 491-498.
102. Donovan MH, Yamaguchi M, Eisch AJ. Dynamic expression of TrkB receptor protein on proliferating and maturing cells in the adult mouse dentate gyrus. Hippocampus 2008; 18: 435-439.
103. Mizuno K, Carnahan J, Nawa H. Brain-derived neurotrophic factor promotes differentiation of striatal GABAergic neurons. Dev Biol 1994; 165: 243-256.
104. Ivkovic S, Ehrlich ME. Expression of the striatal DARPP-32/ARPP-21 phenotype in GABAergic neurons requires neurotrophins in vivo and in vitro. J Neurosci 1999; 19: 5409-5419.
105. Ivkovic S, Polonskaia O, Farinas I, Ehrlich ME. Brain-derived neurotrophic factor regulates maturation of the DARPP-32 phenotype in striatal medium spiny neurons: studies in vivo and in vitro. Neuroscience 1997; 79: 509-516.
106. Ventimiglia R, Mather PE, Jones BE, Lindsay RM. The neurotrophins BDNF, NT-3 and NT-4/5 promote survival and morphological and biochemical differentiation of striatal neurons in vitro. Eur J Neurosci 1995; 7: 213-222.
107. Nakao N, Brundin P, Funa K, Lindvall O, Odin P. Trophic and protective actions of brain-derived neurotrophic factor on striatal DARPP-32-containing neurons in vitro. Brain Res Dev Brain Res 1995; 90: 92-101.
108. Klein R, Conway D, Parada LF, Barbacid M. The trkB tyrosine protein kinase gene codes for a second neurogenic receptor that lacks the catalytic kinase domain. Cell 1990; 61: 647-656.
109. Middlemas DS, Lindberg RA, Hunter T. TrkB, a neural receptor protein-tyrosine kinase: evidence for a full-length and two truncated receptors. Mol Cell Biol 1991; 11: 143-153.
110. Ma B, Culver BP, Baj G, Tongiorgi E, Chao MV, Tanese N. Localization of BDNF mRNA with the Huntington's disease protein in rat brain. Mol Neurodegener 2010; 5: 22.
111. Zuccato C, Ciammola A, Rigamonti D, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001; 293: 493-498.
112. Altar CA, Cai N, Bliven T, et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997; 389: 856-860.
113. Colin E, Zala D, Liot G, et al. Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. EMBO J 2008; 27: 2124-2134.
114. Strand AD, Baquet ZC, Aragaki AK, et al. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci 2007; 27: 11758-11768.
115. Wu CL, Hwang CS, Chen SD, Yin JH, Yang DI. Neuroprotective mechanisms of brain-derived neurotrophic factor against 3-nitropropionic acid toxicity: therapeutic implications for Huntington's disease. Ann N Y Acad Sci 1201: 8-12.
116. Kells AP, Fong DM, Dragunow M, During MJ, Young D, Connor B. AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol Ther 2004; 9: 682-688.
117. Perez-Navarro E, Gavalda N, Gratacos E, Alberch J. Brain-derived neurotrophic factor prevents changes in Bcl-2 family members and caspase-3 activation induced by excitotoxicity in the striatum. J Neurochem 2005; 92: 678-691.
118. Gratacos E, Perez-Navarro E, Tolosa E, Arenas E, Alberch J. Neuroprotection of striatal neurons against kainate excitotoxicity by neurotrophins and GDNF family members. J Neurochem 2001; 78: 1287-1296.
119. Katoh-Semba R, Asano T, Ueda H, et al. Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus. FASEB J 2002; 16: 1328-1330.
120. Borrell-Pages M, Canals JM, Cordelieres FP, et al. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest 2006; 116: 1410-1424.
121. Meisner F, Scheller C, Kneitz S, et al. Memantine upregulates BDNF and prevents dopamine deficits in SIV-infected macaques: a novel pharmacological action of memantine. Neuropsychopharmacology 2008; 33: 2228-2236.
122. Simmons DA, Rex CS, Palmer L, et al. Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice. Proc Natl Acad Sci U S A 2009; 106: 4906-4911.
123. Apostol BL, Simmons DA, Zuccato C, et al. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice. Mol Cell Neurosci 2008; 39: 8-20.
124. Conforti P, Ramos C, Apostol BL, et al. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347. Mol Cell Neurosci 2008; 39: 1-7.
125. Kirschenbaum B, Goldman SA. Brain-derived neurotrophic factor promotes the survival of neurons arising from the adult rat forebrain subependymal zone. Proc Natl Acad Sci USA 1995; 92: 210-214.
126. Zigova T, Pencea V, Wiegand SJ, Luskin MB. Intraventricular administration of BDNF increases the number of newly generated neurons in the adult olfactory bulb. Mol Cell Neurosci 1998; 11: 234-245.
127. Benraiss A, Chmielnicki E, Lerner K, Roh D, Goldman SA. Adenoviral brain-derived neurotrophic factor induces both neostriatal and olfactory neuronal recruitment from endogenous progenitor cells in the adult forebrain. J Neurosci 2001; 21: 6718-6731.
128. Reumers V, Deroose CM, Krylyshkina O, et al. Noninvasive and quantitative monitoring of adult neuronal stem cell migration in mouse brain using bioluminescence imaging. Stem Cells 2008; 26: 2382-2390.
129. Pencea V, Bingaman KD, Wiegand SJ, Luskin MB. Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus. J Neurosci 2001; 21: 6706-6717.
130. Mehler MF, Mabie PC, Zhu G, Gokhan S, Kessler JA. Developmental changes in progenitor cell responsiveness to bone morphogenetic proteins differentially modulate progressive CNS lineage fate. Dev Neurosci 2000; 22: 74-85.
131. Gross RE, Mehler MF, Mabie PC, Zang Z, Santschi L, Kessler JA. Bone morphogenetic proteins promote astroglial lineage commitment by mammalian subventricular zone progenitor cells. Neuron 1996; 17: 595-606.
132. Lim D, Tramontin A, Trevejo J, Herrera D, Garcia-Verdugo J, Alvarez-Buylla A. Noggin antagonizes BMP signaling to create a niche for adult neurogenesis. Neuron 2000; 28: 713-726.
133. Valenzuela DM, Economides AN, Rojas E, et al. Identification of mammalian noggin and its expression in the adult nervous system. J Neurosci 1995; 15: 6077-6084.
134. Smith WC, Harland RM. Expression cloning of noggin a new dorsalizing factor localized to the spemann organizer in xenopus embryos. Cell 1992; 70: 829-840.
135. Mabie PC, Mehler MF, Kessler JA. Multiple roles of bone morphogenetic protein signaling in the regulation of cortical cell number and phenotype. J Neurosci 1999; 19: 7077-7088.
136. Gomes WA, Mehler MF, Kessler JA. Transgenic overexpression of BMP4 increases astroglial and decreases oligodendroglial lineage commitment. Developmental Biology 2003; 255: 164-177.
137. Chmielnicki E, Benraiss A, Economides AN, Goldman SA. Adenovirally expressed noggin and brain-derived neurotrophic factor cooperate to induce new medium spiny neurons from resident progenitor cells in the adult striatal ventricular zone. Journal of Neuroscience 2004; 24: 2133-2142.
138. de Chevigny A, Cooper O, Vinuela A, et al. Fate mapping and lineage analyses demonstrate the production of a large number of striatal neuroblasts after transforming growth factor alpha and noggin striatal infusions into the dopamine-depleted striatum. Stem Cells 2008; 26: 2349-2360.
139. Benraiss A, Bruel-Jungerman E, Lu G, Economides EN, Davidson B, Goldman SA. Sustained induction of neuronal addition to the adult rat neostriatum by AAV4-delivered noggin and BDNF. Gene Ther (in press).
140. Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87: 493-506.
141. Li JY, Popovic N, Brundin P. The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. NeuroRx 2005; 2: 447-464.
142. Bedard A, Gravel C, Parent A. Chemical characterization of newly generated neurons in the striatum of adult primates. Exp Brain Res 2006; 170: 501-512.
143. Lee SW, Trapnell BC, Rade JJ, Virmani R, Dichek DA. In vivo adenoviral vector-mediated gene transfer into balloon-injured rat carotid arteries. Circ Res 1993; 73: 797-807.
144. Kozarsky KF, McKinley DR, Austin LL, Raper SE, Stratford-Perricaudet LD, Wilson JM. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J Biol Chem 1994; 269: 13695-13702.
145. Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, Verma IM. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A 1995; 92: 1401-1405.
146. Sevin C, Benraiss A, van Dam D, et al. Intracerebral adeno-associated virus-mediated gene transfer in rapidly progressive forms of metachromatic leukodystrophy. Hum Mol Genet 2006; 15: 53-64.
147. Peel AL, Klein RL. Adeno-associated virus vectors: activity and applications in the CNS. J Neurosci Methods 2000; 98: 95-104.
148. Bankiewicz KS, Forsayeth J, Eberling JL, et al. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 2006; 14: 564-570.
149. Imayoshi I, Sakamoto M, Ohtsuka T, et al. Roles of continuous neurogenesis in the structural and functional integrity of the adult forebrain. Nat Neurosci 2008; 11: 1153-1161.